{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:16:07Z","timestamp":1792556167594,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009358","name":"Duchenne Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013394","name":"REGENXBIO Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000774","name":"Newcastle University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015461","name":"Audentes Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005693","name":"Parent Project Muscular Dystrophy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medical Genetics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmg.2025.105050","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:57:06Z","timestamp":1760072226000},"page":"105050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Re-evaluating acceptable risk of death from gene therapy: A threshold study among individuals with Duchenne muscular dystrophy and their caregivers in the US and UK"],"prefix":"10.1016","volume":"78","author":[{"given":"Holly","family":"Peay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4592-9919","authenticated-orcid":false,"given":"Megan","family":"McNiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Denger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Camino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Cope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Beaverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Ganot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ione O.C.","family":"Woollacott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bateman-House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Flanigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmg.2025.105050_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ejmg.2025.105050_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ejmg.2025.105050_bib3","doi-asserted-by":"crossref","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","article-title":"Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis","volume":"97","author":"Broomfield","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ejmg.2025.105050_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40271-022-00574-y","article-title":"A comparison of caregiver and patient preferences for treating Duchenne muscular dystrophy","volume":"15","author":"Crossnohere","year":"2022","journal-title":"Patient-Patient-Center Outcome Res."},{"key":"10.1016\/j.ejmg.2025.105050_bib5","series-title":"The Control Preferences Scale","first-page":"21","author":"Degner","year":"1997"},{"key":"10.1016\/j.ejmg.2025.105050_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/hum.2023.29242.ddu","article-title":"Duchenne muscular dystrophy gene therapy in 2023: status, perspective, and beyond","volume":"34","author":"Duan","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejmg.2025.105050_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmg.2025.105050_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40258-019-00521-3","article-title":"Using the threshold technique to elicit patient preferences: an introduction to the method and an overview of existing empirical applications","volume":"18","author":"Hauber","year":"2020","journal-title":"Appl. Health Econ. Health Pol."},{"key":"10.1016\/j.ejmg.2025.105050_bib10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/mus.25411","article-title":"Patient\u2010centered benefit\u2013risk assessment in Duchenne muscular dystrophy","volume":"55","author":"Hollin","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejmg.2025.105050_bib11","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s11136-018-1891-7","article-title":"Engaging patients and caregivers in prioritizing symptoms impacting quality of life for duchenne and becker muscular dystrophy","volume":"27","author":"Hollin","year":"2018","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ejmg.2025.105050_bib12","first-page":"1276","article-title":"A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment","volume":"93","author":"Horton","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmg.2025.105050_bib13","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmg.2025.105050_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmg.2025.105050_bib15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmg.2025.105050_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","article-title":"Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis","volume":"35","author":"Landfeldt","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.ejmg.2025.105050_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting report: 2022 muscular dystrophy association summit on \u2018safety and challenges in gene transfer therapy","volume":"10","author":"Lek","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejmg.2025.105050_bib18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2025.105050_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejmg.2025.105050_bib20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/0883073810371509","article-title":"Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy","volume":"25","author":"McDonald","year":"2010","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ejmg.2025.105050_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/0272989X15581800","article-title":"Validation of a short, 3-item version of the subjective numeracy scale","volume":"35","author":"McNaughton","year":"2015","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.ejmg.2025.105050_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmg.2025.105050_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.genhosppsych.2019.04.002","article-title":"Development of the state optimism measure","volume":"58","author":"Millstein","year":"2019","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.ejmg.2025.105050_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1664","article-title":"Patients' and caregivers' maximum acceptable risk of death for non\u2010curative gene therapy to treat Duchenne muscular dystrophy","volume":"9","author":"Peay","year":"2021","journal-title":"Mol. Genet Genomic Med."},{"key":"10.1016\/j.ejmg.2025.105050_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","article-title":"After patient death, FDA places hold on pfizer Duchenne muscular dystrophy gene therapy trial","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejmg.2025.105050_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmg.2025.105050_bib28","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/archdischild-2014-306366","article-title":"Improving recognition of Duchenne muscular dystrophy: a retrospective case note review","volume":"99","author":"van Ruiten","year":"2014","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejmg.2025.105050_bib29","series-title":"Introductory Econometrics: a Modern Approach","author":"Wooldridge","year":"2013"},{"key":"10.1016\/j.ejmg.2025.105050_bib30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s40267-023-00986-2","article-title":"An overview of recent US-approved gene therapies for Duchenne muscular dystrophy and their respective clinical development programs","volume":"39","author":"Yu","year":"2023","journal-title":"Drugs Ther. Perspect."}],"container-title":["European Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721225000576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721225000576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:29:42Z","timestamp":1773811782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769721225000576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"alternative-id":["S1769721225000576"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmg.2025.105050","relation":{},"ISSN":["1769-7212"],"issn-type":[{"value":"1769-7212","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-evaluating acceptable risk of death from gene therapy: A threshold study among individuals with Duchenne muscular dystrophy and their caregivers in the US and UK","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmg.2025.105050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105050"}}